Insider Trading Alert - TCBI, HUM And HOLX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 10, 2014, 109 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $50.96 to $374,999,999.94.

Highlighted Stocks Traded by Insiders:

Texas Capital (TCBI) - FREE Research Report

Hudgens John who is Chief Risk & Credit Officer at Texas Capital sold 3,000 shares at $64.50 on March 10, 2014. Following this transaction, the Chief Risk & Credit Officer owned 2,983 shares meaning that the stake was reduced by 50.14% with the 3,000-share transaction.

The shares most recently traded at $64.81, up $0.31, or 0.47% since the insider transaction. Historical insider transactions for Texas Capital go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 27,075
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 27,075
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 27,075

The average volume for Texas Capital has been 536,800 shares per day over the past 30 days. Texas Capital has a market cap of $2.7 billion and is part of the financial sector and banking industry. Shares are up 2.88% year-to-date as of the close of trading on Friday.

Texas Capital Bancshares, Inc. operates as the bank holding company for Texas Capital Bank, National Association that provides various banking products and services for commercial businesses, and professionals and entrepreneurs in Texas. The company has a P/E ratio of 23.5. Currently there are 6 analysts that rate Texas Capital a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TCBI - FREE

TheStreet Quant Ratings rates Texas Capital as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Texas Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Humana (HUM) - FREE Research Report

Dunbar Webster Roy who is Director at Humana sold 9,587 shares at $110.30 on March 10, 2014. Following this transaction, the Director owned 1,458 shares meaning that the stake was reduced by 86.8% with the 9,587-share transaction.

The shares most recently traded at $110.88, up $0.58, or 0.52% since the insider transaction. Historical insider transactions for Humana go as follows:

  • 4-Week # shares sold: 1,147
  • 12-Week # shares sold: 1,147
  • 24-Week # shares sold: 22,012

The average volume for Humana has been 1.7 million shares per day over the past 30 days. Humana has a market cap of $17.2 billion and is part of the health care sector and health services industry. Shares are up 7.99% year-to-date as of the close of trading on Friday.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. The stock currently has a dividend yield of 0.97%. The company has a P/E ratio of 14.4. Currently there are 13 analysts that rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HUM - FREE

TheStreet Quant Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hologic (HOLX) - FREE Research Report

Casey Mark J who is SVP, CAO, GC & Secretary at Hologic sold 3,251 shares at $22.53 on March 10, 2014. Following this transaction, the SVP, CAO, GC & Secretary owned 14,470 shares meaning that the stake was reduced by 18.35% with the 3,251-share transaction.

The shares most recently traded at $22.18, down $0.35, or 1.58% since the insider transaction. Historical insider transactions for Hologic go as follows:

  • 4-Week # shares bought: 38,600
  • 4-Week # shares sold: 5,677
  • 12-Week # shares bought: 237,500
  • 12-Week # shares sold: 5,677
  • 24-Week # shares bought: 237,500
  • 24-Week # shares sold: 5,677

The average volume for Hologic has been 2.8 million shares per day over the past 30 days. Hologic has a market cap of $6.0 billion and is part of the health care sector and health services industry. Shares are down 1.66% year-to-date as of the close of trading on Friday.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women. Currently there are 6 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HOLX - FREE

TheStreet Quant Ratings rates Hologic as a hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Hologic Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists